TVTX - Meet members of the 2021 IPO class: Biotechs - 3
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs making their debut in The Russell 2000. Aerovate Therapeutics Clinical-stage biopharma company Aerovate Therapeutics (NASDAQ:AVTE) crashed more than a quarter of its value when it joined the Russell 2000 Index. For its only product candidate AV-101, Aerovate (AVTE) intends to start the enrollment for a Phase 2b portion of its Phase 2b/3 program this year, targeting the patients with pulmonary arterial hypertension (PAH). The disease area came into focus this week amid reports of a potential buyout for the PAH player Acceleron Pharma (NASDAQ:XLRN). The company is said to be in advanced talks to be acquired by Merck (NYSE:MRK) for about $11 billion. The size of the deal has disappointed analysts. Yet,
For further details see:
Meet members of the 2021 IPO class: Biotechs - 3